Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Combination With Bispecific Antibodies for Multiple Myeloma
NCT04108195Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Bispecific Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of daratumumab, talquetamab and teclistamab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 52 weeks, Dose Limiting Toxicity by Severity at 52 weeks and 2 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
daratumumabtalquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04108195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108195.